Dercum’s disease

Search Trials
Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy – ACE Inhibitor Therapy Trial
Status:
Completed
Last Changed:
May 4, 2015
First Changed:
May 4, 2015
Disease(s):
Myocardial Fibrosis
Intervention(s):
Enalapril
The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy
Status:
Terminated
Last Changed:
Jan 14, 2020
First Changed:
Jan 12, 2016
Disease(s):
Muscular Dystrophy
Intervention(s):
Tadalafil 20 MGbeetroot juice extract
Mother-caregivers of Children With Duchenne Muscular Dystrophy
Status:
Completed
Last Changed:
Feb 3, 2016
First Changed:
Aug 13, 2013
Disease(s):
Other Diseases or Conditions
Intervention(s):
sleep parametersHormonal profileInflammatory profileCardiovascular profileMetabolic profile
RZL-012 for Dercum's Disease Lipomas
Status:
Completed
Last Changed:
Feb 26, 2021
First Changed:
Jan 14, 2020
Disease(s):
Dercum's Disease Lipomas
Intervention(s):
RZL-012Vehicle
Evaluation of Safety and Efficacy of RZL-012 for the Treatment of Lipedema or of Nodular Dercum's Disease
Status:
Completed
Last Changed:
May 14, 2019
First Changed:
Apr 10, 2018
Disease(s):
Lipedema
Intervention(s):
RZL-012
Treatment of Women With Lipedema Involving Substantial Fat Above the Knee or of Women and Men With Nodular Dercum's Disease
Status:
Completed
Last Changed:
Sep 6, 2019
First Changed:
Sep 3, 2019
Disease(s):
Dercum Disease
Intervention(s):
RZL-012
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas
Status:
Not yet recruiting
Last Changed:
May 27, 2022
First Changed:
May 24, 2022
Disease(s):
Dercum's Disease
Intervention(s):
10 mg CBL-514 per injection15 mg CBL-514 per injection
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
Status:
Recruiting
Last Changed:
Dec 21, 2021
First Changed:
Apr 5, 2019
Disease(s):
Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention(s):
MaralixibatPlacebo

Connect. Empower. Inspire.